West Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

West Financial Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.49K	Buy	+3	New	+$1.33K	﹤0.01%	179

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

FAF

Fjarde Ap-fonden Stockholm, Sweden $20.9B AUM 36.93% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return

West Financial Advisors's VRTX Position: Q2 2026 in Review

West Financial Advisors opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 3 shares worth $1.49K. The stake represents ﹤0.01% of the portfolio and ranks #179 among its holdings.

605 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

West Financial Advisors held 3 shares of Vertex Pharmaceuticals worth $1.49K as of Q2 2026.
Vertex Pharmaceuticals was a new West Financial Advisors position in Q2 2026.
Vertex Pharmaceuticals made up ﹤0.01% of West Financial Advisors's portfolio in Q2 2026, its #179 holding.
605 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on West Financial Advisors's 13F filing for Q2 2026, filed 8 Jul 2026.